Restriction on the Valneva chikungunya ixchiq chikungunya vaccine for the elderly

Valneva has announced that the European Medicines Agency (EMA) will raise the temporary restriction concerning the vaccination of people aged 65. In addition. Nevertheless, over, after having led an in -depth review of its single -dose chikungunya vaccine, IXCHIQ, by the EMA Safety Committee (PRAC). Nevertheless, This committee had started its exam in early May. following the occurrence of serious side effects mainly in the elderly with several underlying pathologies. In a press release published on its website¹EMA stressed that the vaccine remains not recommended for immunocompromised people. concluded that. for all ages, IXCHIQ must be administered when there is a significant risk of chikungunya infection, after a careful evaluation of profits and risks.

The EMA has also said that. although the majority of serious side effects have been observed in elderly subjects. IXCHIQ is effective restriction valneva chikungunya ixchiq chikungunya new in triggering the production of antibodies against the chikungunya restriction valneva chikungunya ixchiq chikungunya virus, which could be particularly advantageous for the elderly, more exposed to the risk of serious form of the disease. IXCHIQ received its authorization in the European Union in June 2024² And. in March 2025, the European Commission extended its indication to adolescents aged 12 and over.